Lisata Therapeutics (LSTA) 10-Q2020 Q1 Quarterly report

Filed: 7 May 20, 4:12pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: acute, April, assistance, aware, began, biologic, BLA, Buerger, buyer, Canadian, cancer, capability, capable, capacity, cellular, Certificate, clarify, closure, codification, codify, cohort, concurrent, Conference, damage, damaged, debilitated, dedicated, deliberate, demonstrated, disruption, duration, Economic, extent, external, failure, field, fiscal, formal, frequency, higher, highly, hope, hospital, Hubei, infection, inflammation, Jersey, leaving, lung, meant, mortality, native, NJ, NJEDA, Organization, outbreak, outdated, overlapping, pandemic, percentage, permanent, persistent, portion, postpone, preliminary, profitable, pronounced, prove, Province, pulmonary, pursue, Questionnaire, rapidly, recovered, recovery, redundant, regeneration, respiratory, responding, SCAI, score, Seattle, showed, shown, simplify, Society, sought, spending, spread, statistically, stem, stimulate, stimulating, strain, strong, superseded, surfaced, titled, travel, uninterrupted, unique, unrelated, untreatable, vasculature, ventilatory, vessel, Virtual, world, Wuhan

Removed: achieved, Agency, ascertained, ATMP, autoimmune, built, candidate, challenged, chronic, collectively, commenced, committed, complex, conducting, decreased, detailed, device, effectively, efficacy, EMA, end, equipment, European, Fast, finance, gain, holder, iii, immune, immunomodulation, increased, innovative, Japanese, line, Medicinal, NOL, onset, opened, Orphan, payable, PCT, Pharmaceutical, planning, PMDA, proposed, prospective, randomized, reactivated, recent, refundable, restore, Sanford, subjective, sustained, system, taxing, top, track, treated, visit

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated LSTA transcripts

LSTA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Caladrius Biosciences, Inc. (the “Company”) for the quarter ended March 31, 2020 filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Talamo, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:


1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and


2.	The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.

Dated: May 7, 2020



	/s/ Joseph Talamo
	Joseph Talamo
	Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.